2.20

1.35% -0.03

After Hours: 2.19 -0.01 -0.45%

Vyome Holdings Inc (HIND)

Overview News Price History Discussions Forecast

Vyome Holdings Inc stock is traded at $2.20, with a volume of 4,854. It is down -1.35% in the last 24 hours and up +1.85% over the past month. Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Previous Close:

$2.23

Open:

$2.18

24h Volume:

4,854

Relative Volume:

0.19

Market Cap:

$15.44M

Revenue:

$1.34M

Net Income/Loss:

$-13.49M

P/E Ratio:

-0.1773

EPS:

-12.4093

Net Cash Flow:

$-3.07M

1W Performance:

+2.33%

1M Performance:

+1.85%

6M Performance:

-35.48%

1Y Performance:

+0.00%

1-Day Range:

$2.18

$2.235

1-Week Range:

$2.16

$2.30

52-Week Range:

$1.75

$12.87

Vyome Holdings Inc Stock (HIND) Company Profile

Name

Vyome Holdings Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

949-429-6680

Address

1001 CALLE AMANECER, SAN CLEMENTE

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

HIND's Discussions on Twitter

Compare HIND vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIND Vyome Holdings Inc	2.20	15.65M	1.34M	-13.49M	-3.07M	-12.41
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Vyome Holdings Inc Stock (HIND) Latest News

Jul 04, 2026

Price to book forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView

Jul 04, 2026

Jul 02, 2026

HIND Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock HigherRevenue Beat Analysis - dars.gov.et

Jul 02, 2026

Jul 01, 2026

Enterprise value to EBITDA forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView

Jul 01, 2026

Vyome receives Chinese patent for acne treatment formulation - Investing.com

Jul 01, 2026

Vyome receives Chinese patent for acne treatment formulation By Investing.com - Investing.com Canada

Jul 01, 2026

Jun 30, 2026

Enterprise value to revenue forward of Vyome Holdings, Inc. – NASDAQ:HIND - TradingView

Jun 30, 2026

Vyome Holdings Ord Shs (HIND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026

Jun 14, 2026

ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - MSN

Jun 14, 2026

Jun 13, 2026

HIND Q1 2026 Earnings: EPS Surprises Positive as Cost Control Takes Center StageAnalyst Earnings Estimate - newsline.com

Jun 13, 2026

HIND Q1 2026 Earnings: EPS Surprises with 18.3% Beat Amid Revenue UncertaintyFiscal Year Earnings - newsline.com

Jun 13, 2026

Jun 09, 2026

Vyome Holdings (HIND) Declines 3.65% as Stock Tests Key Support ZoneIntraday Trade Ideas - dars.gov.et

Jun 09, 2026

Jun 05, 2026

HIND Q1 2026 Earnings: EPS Beats Estimates as Losses Narrow; Stock RisesCFO Commentary Report - newsline.com

Jun 05, 2026

Jun 04, 2026

Vyome to present VT-1953 Phase 2 data at cancer research meeting - Investing.com

Jun 04, 2026

Jun 03, 2026

Earnings call transcript: Vyome Holdings Q1 2026 shows strong cash position - Investing.com

Jun 03, 2026

May 31, 2026

HIND Q1 2026 Earnings: EPS Beats Estimates as Development Pipeline AdvancesSurprise Factor Analysis - The Legal Advocate

May 31, 2026

May 29, 2026

HIND Q1 2026 Earnings: EPS Surpasses Estimates as Company Advances PipelineROA Comparison - The Legal Advocate

May 29, 2026

Vyome Holdings reports Q1 2026: $8.8M cash, $10.2M total assets, net loss $986K - TradingView

May 29, 2026

HIND Q1 2026 Earnings: Narrower-than-expected loss per share boosts investor sentimentNon-GAAP Earnings - dars.gov.et

May 29, 2026

May 28, 2026

Press Release: Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - Moomoo

May 28, 2026

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet - BioSpace

May 28, 2026

May 27, 2026

HIND Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceDownward Estimate Revision - The Legal Advocate

May 27, 2026

HIND - Finviz

May 27, 2026

May 25, 2026

HIND Q1 2026 Earnings: EPS Beat Despite Limited Revenue VisibilityEPS Consistency Score - The Legal Advocate

May 25, 2026

May 23, 2026